Recent performance and business snapshot

DENTSPLY SIRONA (XRAY) has drawn investor attention after a strong recent price move, with the stock up about 36% over the past month and 12% over the past 3 months.

At a last close of US$14.05, the company carries a market value of about US$2.8b and reports annual revenue of US$3,681.0m, alongside a reported net loss of US$628.0m.

The recent surge in DENTSPLY SIRONA’s share price, including a 14.60% 7 day share price return and 36.01% 30 day share price return, contrasts with a 1 year total shareholder return that is still down 7.91%. This suggests momentum is rebuilding after a weaker few years.

If this rebound has you looking beyond a single healthcare stock, it could be a moment to expand your watchlist using a focused screener for AI driven infrastructure plays such as 54 AI infrastructure stocks

After a move like DENTSPLY SIRONA’s, with the stock rebounding yet longer-term returns still weak and profitability under pressure, the key question is clear: does the current valuation still offer a compelling trade-off between risk and potential reward?

Most Popular Narrative: 69.1% Undervalued

According to the most followed narrative for DENTSPLY SIRONA, a fair value of $45.50 sits well above the recent $14.05 share price. This frames the current rebound in a very different light.

Dentsply Sirona operates in a corner of healthcare that rarely attracts hype but consistently demands precision. As one of the world’s largest dental equipment and consumables providers, the company sits upstream from patient demand, selling to dental practices rather than consumers. That position shapes everything about its business, from revenue stability to growth expectations.

This narrative leans on steady dental procedure volumes, disciplined capital allocation, and a business model built around repeat consumables. It also rests on material improvements in profitability, margins, and cash generation that justify a much higher long term value.

Result: Fair Value of $45.50 (UNDERVALUED)

However, DENTSPLY SIRONA’s recent net loss of US$628.0m and a 3 year total shareholder return that is down 62.6% show that this resilience story can break.

Next Steps

With sentiment around DENTSPLY SIRONA clearly mixed, it makes sense to move quickly and weigh the data against your own expectations before the story shifts. To see what investors currently view as the most promising aspects of the company, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond DENTSPLY SIRONA?

If DENTSPLY SIRONA has sharpened your focus, use this moment to broaden your opportunity set with other stocks that fit clear, disciplined criteria.

• Target potential value opportunities by scanning companies that combine quality fundamentals with appealing pricing using the 47 high quality undervalued stocks.
• Strengthen your watchlist by focusing on companies with resilient financial footing and cleaner balance sheets through the solid balance sheet and fundamentals stocks screener (47 results).
• Unearth less crowded ideas by zeroing in on fundamentally strong businesses that fewer investors are watching via the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.